InvestorsHub Logo
Followers 11
Posts 1538
Boards Moderated 0
Alias Born 08/25/2007

Re: KMBJN post# 110333

Monday, 04/20/2015 2:30:29 PM

Monday, April 20, 2015 2:30:29 PM

Post# of 146240
Exactly KMBJN. Buy More!!!! When you crunch the numbers, lets only consider North American, European, Western markets.

Over-the-counter pharmaceutical sales globally are projected to be US$138 billion in 2017. 36% of those sales are cough, cold, analgesics, and headache medications --that is, medications associated with flu viruses. That is not the total market, but it gives an idea of the potential sales for a Flucide. People will choose to be cured as opposed to relief medicated. Global sales, even without a pandemic could still capture 1/4 of the available market that currently goes toward OTC flu related medicines.

So, $9 billion as a potential market for Flucides. How would that translate into share value?

An even greater percentage of the population will have STD's.

So, $10 billion as a potential market for Herpescides. How would that translate into share value?


Assuming a P/E of a modest 20/1 for a pharma with earnings of only 10% net of gross and we have $480 a share for Flucide and Herpescide. I'm still sticking with the Nanoviricide 5 year Timeline. Anything sooner is simply a bonus.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NNVC News